\u00c0 mesure que le brevet du Gleevec (m\u00e9sylate d’imatinib fabriqu\u00e9 par Novartis) expire au Canada et dans le monde, de plus en plus de versions g\u00e9n\u00e9riques de l’imatinib sont mises sur le march\u00e9. Lorsque l’Imatinib g\u00e9n\u00e9rique est devenu disponible en Ontario, les avis \u00e9taient partag\u00e9s. Nous avons entendu des patients qui, apr\u00e8s \u00eatre pass\u00e9s de la marque Gleevec \u00e0 une forme g\u00e9n\u00e9rique, ont ressenti de nouveaux effets secondaires comme des vomissements et des douleurs semblables \u00e0 celles de l’arthrite. Beaucoup d’autres n’ont connu aucun changement. Mais ce qui est plus inqui\u00e9tant, ce sont les personnes qui ont constat\u00e9 un changement dans leur r\u00e9action.<\/p>\n
Donc, si le g\u00e9n\u00e9rique est identique au produit de marque, pourquoi certains patients pr\u00e9sentent-ils de nouveaux effets secondaires et des changements dans leur r\u00e9ponse ?<\/p>\n
Bien que les versions g\u00e9n\u00e9riques (fabriqu\u00e9es par Apotex, Teva et maintenant Cobalt) du m\u00e9sylate d’imatinib aient \u00e9t\u00e9 jug\u00e9es bio\u00e9quivalentes par Sant\u00e9 Canada – ce qui signifie qu’elles devraient avoir la m\u00eame action dans l’organisme que le Gleevec de marque – chaque version utilise des \u00ab\u00a0excipients\u00a0\u00bb diff\u00e9rents. Un excipient est un agent de charge ajout\u00e9 au m\u00e9dicament pour faciliter le processus de fabrication ou l’absorption et la solubilit\u00e9. L’ajout de ces excipients signifie que les g\u00e9n\u00e9riques sont diff\u00e9rents de la formulation de marque, et peuvent potentiellement affecter la fa\u00e7on dont un patient r\u00e9agit.<\/p>\n
CML-IQ<\/a>, un service d’information bas\u00e9 \u00e0 Montr\u00e9al et ax\u00e9 sur tout ce qui concerne la LMC, a r\u00e9cemment publi\u00e9 les r\u00e9sultats d’une \u00e9tude qu\u00e9b\u00e9coise sur l’efficacit\u00e9 de l’Imatinib g\u00e9n\u00e9rique. Les r\u00e9sultats sont un peu inqui\u00e9tants, car ils montrent que les personnes qui sont pass\u00e9es du Gleevec \u00e0 l’Imatinib g\u00e9n\u00e9rique sont plus susceptibles de pr\u00e9senter une perte de r\u00e9ponse apr\u00e8s avoir \u00e9t\u00e9 sous le g\u00e9n\u00e9rique pendant 1 \u00e0 2 ans. L’\u00e9tude a \u00e9galement montr\u00e9 que si un nombre similaire de patients obtenait une r\u00e9ponse dans les 3 \u00e0 6 premiers mois de traitement par le g\u00e9n\u00e9rique ou le Gleevec, la probabilit\u00e9 d’une r\u00e9ponse mol\u00e9culaire pr\u00e9coce \u00e9tait plus faible avec le g\u00e9n\u00e9rique. Pour en savoir plus sur cette \u00e9tude , cliquez ici<\/a>.<\/p>\n Bien qu’il reste encore beaucoup \u00e0 faire pour d\u00e9terminer si les versions g\u00e9n\u00e9riques de l’imatinib sont aussi efficaces que le Gleevec, les patients qui ont chang\u00e9 de m\u00e9dicament peuvent prendre certaines mesures pour g\u00e9rer leur sant\u00e9.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Le brevet du Gleevec arrivant \u00e0 expiration, de plus en plus de patients passent \u00e0 un g\u00e9n\u00e9rique. Mais est-ce la m\u00eame chose ?<\/p>\n","protected":false},"author":2,"featured_media":1280,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_uag_custom_page_level_css":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[203,206],"tags":[214,210,281,283,264],"class_list":["post-1567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-premiere-page","category-science-etc","tag-bien-vivre-avec-la-lmc","tag-cml-fr-2","tag-gleevec-generique","tag-imatinib-generique","tag-lisa-machado-fr"],"aioseo_notices":[],"uagb_featured_image_src":{"full":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection.jpg",600,400,false],"thumbnail":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection-150x150.jpg",150,150,true],"medium":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection-300x200.jpg",300,200,true],"medium_large":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection.jpg",600,400,false],"large":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection.jpg",600,400,false],"1536x1536":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection.jpg",600,400,false],"2048x2048":["https:\/\/cmlnetwork.ca\/wp-content\/uploads\/2014\/02\/Grafitti-reflection.jpg",600,400,false]},"uagb_author_info":{"display_name":"cmlnetwork","author_link":"https:\/\/cmlnetwork.ca\/fr\/author\/cmlnetwork\/"},"uagb_comment_info":0,"uagb_excerpt":"Le brevet du Gleevec arrivant \u00e0 expiration, de plus en plus de patients passent \u00e0 un g\u00e9n\u00e9rique. Mais est-ce la m\u00eame chose ?","_links":{"self":[{"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/posts\/1567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/comments?post=1567"}],"version-history":[{"count":0,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/posts\/1567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/media\/1280"}],"wp:attachment":[{"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/media?parent=1567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/categories?post=1567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cmlnetwork.ca\/fr\/wp-json\/wp\/v2\/tags?post=1567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n